Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected

Reuters12-20 18:47

LONDON/COPENHAGEN, Dec 20(Reuters) - Novo Nordisk

said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected.

The lower-than-expected weight loss from the drug candidate deals a blow to the Danish drugmaker's ambitions for a successor to its popular Wegovy more powerful than Eli Lilly's Zepbound.

Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market.

(Reporting by Maggie Fick in London and Stine Jacobsen and Louise Rasmussen in Copenhagen, Ludwig Burger in Frankfurt; Editing by Josephine Mason and Catherine Evans)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment